My greetings and well wishes to all of you for your good health and inspiring work in cancer and community care.

On behalf of the Immuno-oncology Society of India(I-OSI), I am pleased to welcome you for the 2nd Annual National Congress to be held as a three days virtual programme on October 30th to 31st (4 PM - 9 PM India Standard Time) and Nov 1st, 2020 (9 AM - 1.30 PM IST).

This conference will assess the current state of immuno-oncology that highlights for cancer care professionals the current research, utilization trends, and coming advances for immunotherapies. Hence, the theme of this year’s conference is “Immuno-Oncology towards 2021: Reboot, Resolve and Evolve”.

The huge learning curve that immuno-oncology presented has significantly flattened out just by virtue of the explosive availability of immuno-oncology therapies in cancer care. In many cases, it has become the standard of care, and if you want to practice oncology today, you have to keep yourself abreast with the new tricks. The IOSICON 2020 therefore aims to meet these needs of multidisciplinary care teams and describes next steps for supporting optimal delivery of immunotherapies.

With 3876 agents and 469 targets in 2019 the recent white paper points to the likelihood of further expansion of immunotherapy to treat more patients in the future. Factors that support this belief include the emergence of checkpoint inhibitors as feasible therapies in a variety of adjuvant and neoadjuvant settings, an increase in utilization of immuno-oncology therapies as part of combination regimens or in sequence with chemotherapy or targeted agents, and the increase of immuno-oncology delivery in the community setting.

Additionally, I-OSICON will also try to address survivorship needs, which includes unpredictable and delayed immune-related adverse events, follow-up, and psychosocial support.

For over 2 years, I-OSI has been the leader in promoting tumor immunology and advancing cancer immunotherapy education, information and research in India. As the paradigm in cancer treatment changes, I-OSI Annual Meeting continues to lead and drive the numerous advances our field is making.

We have various sponsorship opportunities for pharma partners and we request you to get in touch with our event manager and discuss the same.

Looking forward to your whole hearted support. 

Regards,

Organizing Secretory, I-OSICON- 2 

Founder General Secretary: Immuno-Oncology Society of India (I-OSI) 

Professor, Medical Oncology, Tata Memorial Centre, Mumbai, India